This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Report Card 2004: Biotech Hits and Misses

And what was I thinking when I figured value investors would appreciate Intermune (ITMN) for its work to develop a new hepatitis-C drug? Obviously, I wasn't thinking at all! Too many problems at Intermune and too long to wait for a turnaround. Grade: C.

I still like Biomarin Pharmaceuticals (BMRN - Get Report), but distractions and managerial screwups have made this a trying year. I'm tempted to take an incomplete, but the taskmaster in me says "C."

I took an incomplete on Sonus Pharmaceuticals (SNUS) last year , figuring that 2004 would be the year of major progress on its Taxol reformulation. Stupid me. Grade: D.

The incomplete list for the year includes American Pharmaceutical Partners (APPX), though an FDA decision on its breast cancer drug Abraxane is due on or before Jan. 8. I'll also take a wait-and-see on my latest controversial and bearish pick, Celgene (CELG - Get Report). On the bull side of the ledger, it's been a long year of waiting for Axonyx (AXYX), but an incomplete is necessary until clinical data are made public early next year.

I'm sure I'm forgetting some good picks and pans for the year. If you think I'm neglecting something, or if you take issue with some of my grades, drop me a line.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. He invites you to send your feedback to .
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ITMN $73.89 -0.03%
BMRN $65.11 0.00%
BIIB $249.99 0.00%
CELG $100.50 0.00%
PG $82.64 0.00%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs